Part of the Pemphigus & Bullous Disorders Knowledge Library
The Connection Between Environmental Triggers and Vesiculobullous Skin Diseases
Vesiculobullous skin diseases, such as pemphigus vulgaris, bullous pemphigoid, and epidermolysis bullosa, are chronic conditions that cause painful blisters and lesions on the skin and mucous membranes. While these disorders are often linked to genetic and autoimmune factors, environmental triggers can also play a significant role in exacerbating symptoms and influencing the severity and frequency of flare-ups. Understanding how environmental factors impact these conditions can provide valuable insights into effective management strategies and improve the quality of life for individuals affected by vesiculobullous skin diseases (Fine et al., 2014).
The Connection Between Environmental Triggers and Vesiculobullous Skin Diseases
Vesiculobullous skin diseases encompass a group of disorders characterized by blister formation in response to structural or immune disruptions in the skin layers. The main categories of these diseases include:
Environmental factors can worsen the symptoms of vesiculobullous skin diseases by influencing immune responses, skin integrity, and inflammation. Some of the most common environmental triggers include:
Ultraviolet (UV) radiation from the sun can exacerbate inflammation, weaken skin integrity, and trigger immune responses, leading to flare-ups in vesiculobullous diseases (Eisen et al., 2017).
Extreme temperatures and humidity levels can have a profound effect on the skin, particularly in individuals with vesiculobullous diseases. Hot, humid conditions can increase sweating, while cold, dry conditions can lead to skin dryness and cracking (Has et al., 2020).
Airborne pollutants, including smog, chemicals, and particulate matter, can trigger inflammation and worsen symptoms in people with vesiculobullous skin diseases (Kim et al., 2016).
Everyday contact with irritants and allergens, such as certain fabrics, chemicals, and skincare products, can worsen symptoms in individuals with vesiculobullous skin diseases.
Ayurveda emphasizes the importance of balance in maintaining overall health and recognizes that environmental factors can disrupt doshic harmony, leading to skin and immune issues. Environmental triggers can aggravate the doshas—Vata, Pitta, and Kapha—each affecting vesiculobullous conditions differently (Tiwari, 2001).
At EliteAyurveda, we incorporate Ayurvedic principles to help patients adapt to environmental changes, minimize flare-ups, and manage vesiculobullous diseases holistically.
Ayurveda offers natural solutions to counteract environmental triggers by incorporating lifestyle practices, dietary adjustments, and skin care tailored to each patient’s unique constitution. Here’s how we help patients manage these triggers effectively:
For patients with vesiculobullous diseases, minimizing sun exposure is essential to prevent flare-ups. Ayurveda recommends protective practices and soothing remedies to counteract UV damage.
Ayurvedic practices emphasize keeping the skin cool and hydrated in hot weather and protected in cold conditions.
Protecting the skin from pollutants and toxins is crucial to prevent inflammation and irritation in vesiculobullous conditions.
Minimizing exposure to irritants and allergens is essential for managing vesiculobullous conditions. Ayurveda recommends using natural and gentle products for sensitive skin.
By understanding and managing environmental triggers, individuals with vesiculobullous skin diseases can achieve better control over symptoms and reduce the frequency and severity of flare-ups. Key benefits of this approach include:
Related-
Know More About Ayurveda Treatment For skin Dermatology.
GET IN TOUCH
Contact us
1.Didona D, Di Zenzo G. Humoral epitope spreading in autoimmune bullous diseases. Front Immunol 2018;9:779. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Wang WM, Guo L, Jin HZ. Role of B cells in immune-mediated dermatoses. Mol Immunol 2020;126:95-100. [DOI] [PubMed] [Google Scholar]
3.Pile HD, Yarrarapu SNS, Crane JS. Drug induced pemphigus. St. Petersburg (FL), USA: StatPearls Publishing; 2020. [PubMed] [Google Scholar]
4.Hibi A, Kasahara Y, Ishihara Y, et al. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen- DQB1\*03:01. CEN Case Rep 2020;9:189-94. [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Tur E, Brenner S. Contributing exogenous factors in pemphigus. Int J Dermatol 1997;36:888-93. [DOI] [PubMed] [Google Scholar]
6.Krain LS. Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955-1973. Arch Dermatol 1974;110:862-5. [DOI] [PubMed] [Google Scholar]
7.Ruocco E, Ruocco V, Lo Schiavo A, et al. Viruses and pemphigus: an intriguing never-ending story. Dermatology 2014;229:310-5. [DOI] [PubMed] [Google Scholar]
8.Mohammadi F, Khalili Z, Marashi SM, et al. The potential roles of herpesvirus and cytomegalovirus in the exacerbation of pemphigus vulgaris. Dermatol Pract Concept 2018;8:262-71. [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Ren Z, Hsu D, Brieva J, Silverberg JI. Association between climate, pollution and hospitalization for pemphigus in the USA. Clin Exp Dermatol 2019;44:135-43. [DOI] [PubMed] [Google Scholar]
10.Fisher KR, Higginbotham R, Frey J, et al. Pesticide-associated pemphigus vulgaris. Cutis 2008;82:51-4. [PubMed] [Google Scholar]
11.Tsankov N, Vassileva S, Kamarashev J, et al. Epidemiology of pemphigus in Sofia, Bulgaria. A 16-year retrospective study (1980-1995). Int J Dermatol 2000;39:104-8. [DOI] [PubMed] [Google Scholar]
12.Kyriakis KP, Vareltzidis AG, Tosca AD. Environmental factors influencing the biologic behavior of patterns of pemphigus vulgaris: epidemiologic approach. Int J Dermatol 1995;34:181-5. [DOI] [PubMed] [Google Scholar]
13.Salmanpour R, Shahkar H, Namazi MR, Rahman-Shenas MR. Epidemiology of pemphigus in south-western Iran: a 10-year retrospective study (1991-2000). Int J Dermatol 2006;45:103-5. [DOI] [PubMed] [Google Scholar]
14.Robati RM, Saeedi M, Alirezayee P. Pemphigus vulgaris and season: are they really related or not? J Eur Acad Dermatol Venereol 2011;25:1235-6. [DOI] [PubMed] [Google Scholar]
15.Marzano AV, Trevisan V, Eller-Vainicher C, et al. Evidence for vitamin D deficiency and increased prevalence of fractures in autoimmune bullous skin diseases. Br J Dermatol 2012;167:688-91. [DOI] [PubMed] [Google Scholar]
16.Marzano AV, Trevisan V, Cairoli E, et al. Vitamin D and skeletal health in autoimmune bullous skin diseases: a case control study. Orphanet J Rare Dis 2015;10:8. [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Tukaj S, Schmidt E, Recke A, et al. Vitamin D status in bullous pemphigoid patients. Br J Dermatol 2013;168:873-4. [DOI] [PubMed] [Google Scholar]
18.Zarei M, Javanbakht MH, Chams-Davatchi C, et al. Evaluation of vitamin D status in newly diagnosed pemphigus vulgaris patients. Iran J Public Health 2014;43:1544-9. [PMC free article] [PubMed] [Google Scholar]
19.Tavalkopour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol Res 2018;310:95-106. [DOI] [PubMed] [Google Scholar]
20.Shear NH. Diagnosing cutaneous adverse reactions to drugs. Arch Dermatol 1990;126:94-7. [PubMed] [Google Scholar]
21.Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol 2011;29:455-7. [DOI] [PubMed] [Google Scholar]
22.Lo Schiavo A, Ruocco E, Brancaccio G, et al. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol 2013;31:391-9. [DOI] [PubMed] [Google Scholar]
23.Fang H, Shen S, Zheng X, et al. Association of HLA class I and class II alleles with bullous pemphigoid in Chinese Hans. J Dermatol Sci 2018;89:258-62. [DOI] [PubMed] [Google Scholar]
24.Ujiie H, Muramatsu K, Mushiroda T, et al. HLA-DQB1\*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. J Invest Dermatol 2018;138:1201-4. [DOI] [PubMed] [Google Scholar]
25.Moro F, Fania L, Sinagra JLM, et al. Bullous pemphigoid: trigger and predisposing factors. Biomolecules 2020;10:1432. [DOI] [PMC free article] [PubMed] [Google Scholar]
Medical disclaimer. This article is for general information and is not a substitute for personalised medical advice. Ayurvedic treatment at EliteAyurveda is individualised following clinical assessment. Do not start, stop or alter any prescribed medication without consulting your treating physician.